Richard M Goldberg

Richard M Goldberg

UNVERIFIED PROFILE

Are you Richard M Goldberg?   Register this Author

Register author
Richard M Goldberg

Richard M Goldberg

Publications by authors named "Richard M Goldberg"

Are you Richard M Goldberg?   Register this Author

100Publications

4301Reads

21Profile Views

Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer.

Clin Gastroenterol Hepatol 2019 Dec 4. Epub 2019 Dec 4.

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2019.11.046DOI Listing
December 2019

Reply to S. Sorscher.

J Clin Oncol 2019 Sep 3;37(25):2291-2293. Epub 2019 Jul 3.

Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01366DOI Listing
September 2019

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

CA Cancer J Clin 2019 Jul 22;69(4):305-343. Epub 2019 May 22.

Professor of Medicine and Oncology, Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Institute, MedStar Georgetown Cancer Institute, Washington, DC.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21560
Publisher Site
http://dx.doi.org/10.3322/caac.21560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767457PMC
July 2019

Promising New Agents for Colorectal Cancer.

Curr Treat Options Oncol 2018 05 11;19(6):29. Epub 2018 May 11.

West Virginia University Cancer Institute, P.O. Box 9300, 1801 HSS, 1 Medical Center Drive, Morgantown, WV, 26506, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0543-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499928PMC
May 2018

Hypermutated Tumors and Immune Checkpoint Inhibition.

Drugs 2018 Feb;78(2):155-162

West Virginia University Cancer Institute, P.O. Box 9300, 1801 HSS, 1 Medical Center Drive, Morgantown, WV, 26506, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0863-0DOI Listing
February 2018

In Reply.

Oncologist 2018 01 13;23(1):136. Epub 2017 Nov 13.

Department of Biomedical Informatics, Ohio State University Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759828PMC
January 2018

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

J Clin Oncol 2017 Nov 4;35(32):3671-3677. Epub 2017 Oct 4.

Charles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.2130
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.2130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678342PMC
November 2017

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

J Clin Oncol 2017 Oct 17;35(29):3338-3346. Epub 2017 Aug 17.

Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9011DOI Listing
October 2017

The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.

Oncologist 2017 09 15;22(9):1015-1019. Epub 2017 Jun 15.

Department of Biomedical Informatics, Ohio State University Center for Biostatistics, Ohio State University, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599203PMC
September 2017

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

J Clin Oncol 2017 Jun 17;35(17):1929-1937. Epub 2017 Apr 17.

Lindsay A. Renfro, Axel Grothey, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Richard M. Goldberg, The Ohio State University, Columbus, OH; Alberto Sobrero, Ospedale San Martino, Genoa; Alfredo Falcone, University Hospital of Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil; Christophe Tournigand, Assistance Hopitaux Publique de Paris Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs; Dana-Farber Cancer Institute, Boston, MA; Eduardo Diaz-Rubio, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Paulo M. Hoff, Hospital Sírio-Libanês and University of São Paulo, São Paulo, Brazil; Fairooz F. Kabbinavar and J. Randolph Hecht, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, University of Amsterdam, Amsterdam, the Netherlands; John Souglakos, University of Crete, Heraklion, Greece; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; and Leonard Saltz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5771DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466009PMC
June 2017

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

J Natl Cancer Inst 2017 05 31;109(5). Epub 2016 Dec 31.

Affiliations of authors: Department of Gastroenterology and GI Oncology, Université Paris Descartes, Hopital Européen Georges Pompidou, Paris, France (JTai); Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France (KLM); Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (QS, DJS); Department of Pathology, Centre Jean Perrin, EA ERTICa, Université d'Auvergne, Clermont-Ferrand, France (FPL); Centre Hospitalier Universitaire Robert Debré, Reims, France (OB); Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain (JTab); Spanish Gastrointestinal Tumors TTD Group, Universitat Autònoma de Barcelona, Barcelona, Spain (JTab); Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy (EM); Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH (RMG); First Medical Department, University Hospital Carl Gustav Carus, Dresden, Germany (GF); Department of Gastroenterology, Hôpital Universitaire Erasme, Brussels, Belgium (JLVL); Department of Oncology, Mayo Clinic and Mayo Cancer Center, Rochester, MN (SRA, FAS); Pathology Department, Ambroise Paré Hospital, Boulogne, France (JFE); Université Paris Descartes, Sorbonne Paris Cité, France (PLP); Assistance Publique Hôpitaux de Paris, Department of Biology, Hôpital Européen Georges Pompidou, Paris, France (PLP); INSERM UMR-S1147, Paris, France (PLP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075212PMC
May 2017

Reply to L. Casadaban et al.

J Clin Oncol 2017 04 23;35(12):1373-1374. Epub 2017 Jan 23.

Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.2646
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.2646DOI Listing
April 2017

Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable.

JAMA Oncol 2017 Feb;3(2):165-166

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3777DOI Listing
February 2017

Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy.

JAMA Oncol 2016 Dec;2(12):1537-1538

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3642DOI Listing
December 2016

In Memoriam: A Tribute to Daniel J. Sargent, Ph.D.

Oncologist 2016 12 7;21(12):1540-1541. Epub 2016 Nov 7.

Department of Medicine, School of Medicine and James Cancer Hospital and Soloff Research Center, The Ohio State University, Columbus, Ohio, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153349PMC
December 2016

Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.

Genet Med 2016 09 11;18(9):863-8. Epub 2016 Feb 11.

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/gim.2015.184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489337PMC
September 2016

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

J Clin Oncol 2016 09 18;34(25):3047-53. Epub 2016 Jul 18.

Donna Niedzwiecki and Xing Ye, Duke University, Durham; Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC; Wendy L. Frankel and Richard M. Goldberg, The Ohio State University, Columbus, OH; Alan P. Venook and Robert S. Warren, University of California-San Francisco, San Francisco, CA; Paula N. Friedman, The University of Chicago, Chicago, IL; Robert J. Mayer, Dana-Farber Cancer Institute; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Thomas Anthony Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, Peter Kerr, Richard D. Kennedy, and D. Paul Harkin, Almac Diagnostics, Craigavon; Patrick G. Johnston, Queen's University, Belfast, Northern Ireland; and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.4699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012711PMC
September 2016

Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.

Sci Rep 2016 09 14;6:33273. Epub 2016 Sep 14.

University of Miami Miller School of Medicine, Division of Biostatistics, Department of Public Health Sciences, Miami, 33136, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep33273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021945PMC
September 2016

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

J Clin Oncol 2016 08 5;34(23):2736-42. Epub 2016 Jul 5.

Peter C. Enzinger and Robert J. Mayer, Dana-Farber Cancer Institute, Harvard Medical School, and Alliance for Clinical Trials in Oncology, Boston, MA; Barbara Ann Burtness and Steven J. Cohen, Fox Chase Cancer Center; Barbara Ann Burtness, Steven J. Cohen, and Al Bowen Benson III, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Philadelphia, PA; Donna Niedzwiecki, Xing Ye, and Kathe Douglas, Alliance Statistics and Data Center, Duke University, Durham, NC; David H. Ilson, Memorial Sloan Kettering Cancer Center and Alliance for Clinical Trials in Oncology, New York, NY; Victoria Meucci Villaflor, University of Chicago Medicine and Alliance for Clinical Trials in Oncology; Al Bowen Benson III, Northwestern University Feinberg School of Medicine, Chicago, IL; Alan Venook, University of California San Francisco Helen Diller Family Comprehensive Cancer Center and Alliance for Clinical Trials in Oncology, San Francisco, CA; and Richard M. Goldberg, Ohio State University James Comprehensive Cancer Center and Alliance for Clinical Trials in Oncology, Columbus, OH.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/06/30/JCO.2015.65
Web Search
http://dx.doi.org/10.1200/JCO.2015.65.5092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019745PMC
August 2016

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Pharmacogenet Genomics 2016 Mar;26(3):133-7

aDepartment of Molecular Pharmacology and Experimental Therapeutics (MPET), Mayo Clinic Cancer Center bAlliance Statistics and Data Center cDivision of Medical Oncology dDivision of Gastroenterology, Mayo Clinic, Rochester, Minnesota eDepartment of Surgery, Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, Hawaii fDepartment of Medicine, Center for GI Oncology, The University of Chicago Medicine, Chicago, Illinois gDivision of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee hSurgical Oncology Associates of South Texas, San Antonio, Texas iDepartment of Hematology Oncology, Lehigh Valley Health Network, John and Dorthy Morgan Cancer Center, Allentown, Pennsylvania jDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan kDepartment of Hematology/Oncology, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA lDepartment of Medicine, Division of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738010PMC
March 2016

Colorectal clinical trials: what is on the horizon?

Future Oncol 2016 Feb 18;12(4):525-31. Epub 2016 Jan 18.

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 460 W 10th Ave., Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976598PMC
February 2016

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

J Clin Oncol 2016 Jan 26;34(2):144-50. Epub 2015 Oct 26.

Lindsay A. Renfro and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Fotios Loupakis and Alfredo Falcone, Azienda Ospedaliero-Universitaria Pisana and Università di Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital Cancer Center, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Institut de Cancerologie, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil, Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs, Dana-Farber Cancer Institute Boston, MA; Eduardo Diaz-Rubio, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; J. Randolph Hecht, David Geffen School of Medicine at the University of California at Los Angeles; Heinz-Josef Lenz, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; Richard M. Goldberg, Ohio State University, Columbus, OH; and Leonard B. Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.6441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070548PMC
January 2016

Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?

Oncologist 2015 Dec 28;20(12):1448-56. Epub 2015 Oct 28.

The Ohio State James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679091PMC
December 2015

Update on Anti-Angiogenesis Therapy in Colorectal Cancer.

Curr Colorectal Cancer Rep 2015 Dec;11(6):378-387

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11888-015-0292-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991548PMC
December 2015

Managing choices for older patients with colon cancer: adjuvant therapy.

Am Soc Clin Oncol Educ Book 2013

From the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e190DOI Listing
November 2015

Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.

J Natl Cancer Inst 2015 Oct 9;107(10). Epub 2015 Jul 9.

Mayo Clinic, Rochester, MN (HHY, SRA, SNT, FAS); Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (QS, DJS); Division of Medical Oncology, The Ohio State University, Columbus, OH (RMG).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758035PMC
October 2015

Recent therapeutic advances in the treatment of colorectal cancer.

Annu Rev Med 2015 9;66:83-95. Epub 2014 Oct 9.

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210; email: , ,

View Article

Download full-text PDF

Source
http://www.annualreviews.org/doi/10.1146/annurev-med-051513-
Publisher Site
http://dx.doi.org/10.1146/annurev-med-051513-102539DOI Listing
September 2015

Reply to J.N. Primrose et al and C.-H. Köhne.

J Clin Oncol 2015 Jul 1;33(21):2408-9. Epub 2015 Jun 1.

The James Cancer Hospital and Solove Research Institute, The Ohio State University James Comprehensive Cancer Center, Columbus, OH

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.4751DOI Listing
July 2015

MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.

PLoS One 2014 13;9(10):e108483. Epub 2014 Oct 13.

Department of Immunology, University of Washington, Seattle, Washington, United States of America; Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, Washington, United States of America; Department of Pathology, University of Washington Medical School, Seattle, Washington, United States of America; Department of Biochemistry, University of Washington, Seattle, Washington, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108483PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195600PMC
June 2015

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

N Engl J Med 2015 Jun 30;372(26):2509-20. Epub 2015 May 30.

From the Swim Across America Laboratory (D.T.L., J.N.U., B.R.B., L.A.D.), Sidney Kimmel Comprehensive Cancer Center (D.T.L., J.N.U., H.W., H.K., A.D.E., A.D.S., B.S.L., N.S.A., D.L., B.B., R.C.D., D.M.P., N.P., K.W.K., S.Z., B.V., L.A.D.), Ludwig Center and Howard Hughes Medical Institute (B.R.B., A.D.S., N.P., K.W.K., S.Z., B.V., L.A.D.), and the Departments of Radiology (A.Z.) and Pathology (F.B., T.H., R.H.H., L.D.W., N.C., T.C.C., J.M.T., R.A.A., J.R.E.), Johns Hopkins University School of Medicine, Baltimore; Department of Medicine, Stanford University School of Medicine, Stanford, CA (G.A.F.); Providence Cancer Center at Providence Health and Services, Portland, OR (T.S.C.); Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh (J.J.L.); Bon Secours Cancer Institute, Richmond, VA (S.M.D.); Division of Medical Oncology, Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, and Human Cancer Genetics Program, Ohio State University Comprehensive Cancer Center, Columbus (R.M.G., A.C.); and Merck, Kenilworth, NJ, and North Wales, PA (M.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1500596DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481136PMC
June 2015

Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.

PLoS One 2014 11;9(4):e94727. Epub 2014 Apr 11.

DeBartolo Family Personalized Medicine Institute, Division of Population Sciences, Moffitt Cancer Center, Tampa, Florida, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094727PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984266PMC
May 2015

Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.

J Clin Oncol 2015 Jan 27;33(1):36-41. Epub 2014 Oct 27.

Manish R. Sharma, Elizabeth Gray, and Theodore G. Karrison, University of Chicago, Chicago, IL; Richard M. Goldberg, Ohio State University, Columbus, OH; and Daniel J. Sargent, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.2826DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268251PMC
January 2015

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

J Clin Oncol 2015 Jan 10;33(1):22-8. Epub 2014 Nov 10.

Qian Shi, Axel Grothey, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Aimery de Gramont and Benoist Chibaudel, Hospital Saint Antoine; Christophe Tournigand, Université Paris Est Créteil, Paris; Jean-Yves Douillard, Institute of Cancer Research in Western, St Herblain, France; John Zalcberg, Monash University; Niall C. Tebbutt, Austin Health, Melbourne, Victoria, Australia; Hans-Joachim Schmoll, Martin-Luther University, Halle; Rainer Porschen, Klinikum Bremen-Ost, Bremen; Volker Heinemann, University of Munich, München; Carsten Bokemeyer, University Hospital, Hamburg-Eppendorf, Germany; Matthew T. Seymour, Cancer Research UK Clincal Center, Leeds; Richard Adams, Cardiff University, Cardiff, United Kingdom; Leonard Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY; Richard M. Goldberg, Ohio State University, Columbus, OH; Cornelis J.A. Punt, Academic Medical Center, Amsterdam, the Netherlands; Paulo M. Hoff, Hospital Sírio-Libanês, Sao Paulo, Brazil; Joel Randolph Hecht and Fairooz F. Kabbinavar, University of California at Los Angeles, Los Angeles, CA; Herbert Hurwitz, Duke University, Durham, NC; Eduardo Díaz-Rubio, Hospital Clinico San Carlos, Madrid, Spain; Charles Fuchs, Dana-Farber Cancer Institute, Boston, MA; John Souglakos, University of Crete, Heraklion, Greece; Alfredo Falcone, University of Pisa, Pisa, Italy; Eric Van Cutsem, University Hospital Gasthuisberg, Leuven; and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.5887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482837PMC
January 2015

Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?

J Clin Oncol 2015 Jan 17;33(3):241-3. Epub 2014 Nov 17.

The Ohio State University James Comprehensive Cancer Center, Columbus, OH

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.3989DOI Listing
January 2015

Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).

J Natl Cancer Inst 2015 Jan 27;107(1):336. Epub 2014 Nov 27.

Massachusetts General Hospital Cancer Center, Boston, MA (EL); Departments of Medicine, and Health Care Policy, Harvard Medical School, Boston, MA (EL, YH, AM); American Society of Clinical Oncology, Alexandria, VA (RLS); Department of Medicine, University of North Carolina, Chapel Hill, NC (HM); Department of Medicine, Duke University, Durham, NC (HJC); City of Hope, Duarte, CA (AH); Department of Medicine, University of Chicago, Chicago, IL (HLK); Department of Medicine, University of California San Francisco, San Francisco, CA (AV); Yale Cancer Center, New Haven, CT (RL); Department of Medicine, the University of Tennessee, Memphis, TN (HN); Department of Medicine, Ohio State University, Columbus, OH (RMG); Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (SJ).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271075PMC
January 2015

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

J Natl Cancer Inst 2015 Jan 27;107(1):345. Epub 2014 Nov 27.

: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (KN, JAM, KS, JAC, RJM, SO, CSF); Division of Gastroenterology, Massachusetts General Hospital, Boston, MA (ATC); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA (ATC, ELG, CSF); Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC (DN); Memorial Sloan-Kettering Cancer Center, New York, NY (LBS); Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL (ABB); Toledo Community Hospital Oncology Program, Toledo, OH (PLS); Hopital du Sacre-Coeur de Montreal, Universite de Montreal, Quebec, Canada (RW); Edward Cancer Center, Naperville, IL (AH); Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH (RMG); Division of Medical Oncology, University of California at San Francisco, San Francisco, CA (APV); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology (SO, ELG) and Department of Nutrition (ELG), Harvard School of Public Health, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271076PMC
January 2015

Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management.

J Gastrointest Surg 2014 Dec 10;18(12):2186-91. Epub 2014 Oct 10.

Division of Surgical Oncology, The Ohio State University Wexner Medical Center, 410 West 10th Ave, N924 Doan Hall, Columbus, OH, 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-014-2670-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809042PMC
December 2014

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

J Natl Cancer Inst 2014 Dec 7;106(12). Epub 2014 Nov 7.

Department of Molecular Pharmacology and Experimental Therapeutics (AML, RBD), Alliance Statistics and Data Center (QS, EP, DJS), Division of Medical Oncology (SRA, FAS, RBD), Division of Gastroenterology (FAS), Mayo Clinic Cancer Center, Rochester, MN; Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, HI (JLB); Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH (RMG).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271081PMC
December 2014

How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?

Curr Colorectal Cancer Rep 2014 Dec;10(4):372-379

Division of Medical Oncology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11888-014-0244-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226466PMC
December 2014

Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.

Clin Colorectal Cancer 2014 Sep 23;13(3):156-163.e2. Epub 2014 Jun 23.

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2014.04.001DOI Listing
September 2014

Prostate cancer incidence in males with Lynch syndrome.

Genet Med 2014 Jul 16;16(7):553-7. Epub 2014 Jan 16.

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/gim.2013.193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289599PMC
July 2014

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.

Cancer Chemother Pharmacol 2014 Jul 13;74(1):117-23. Epub 2014 May 13.

Department of Medicine, Division of Hematology/Oncology, School of Medicine, The University of North Carolina at Chapel Hill, Physicians Office Building, 170 Manning Drive, Campus Box #7305, Chapel Hill, NC, 27599, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2474-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517671PMC
July 2014

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

J Natl Cancer Inst 2014 Jul 12;106(7). Epub 2014 Jun 12.

Affiliations of authors: Division of Hematology/Division of Medical Oncology (WIG), Division of Biomedical Statistics & Informatics (MRM, GDN), Cancer Center Statistics (DJS), Division of Medical Oncology (SRA, AG, JMH, RRM), Division of Gastroenterology & Hepatology/Division of Medical Oncology (FAS), Division of Gastroenterology & Hepatology (PJL), Molecular Genetics (SNT), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Division of Medical Oncology, Ohio State University, Columbus, OH (RMG); Division of Hematology/Oncology, Vanderbilt University, Nashville, TN (EC); Section of Hematology/Medical Oncology, Lehigh Valley Health Network, Allentown, PA (SN); Cancer Prevention & Control Program, University of Hawaii Cancer Center, Honolulu, HI (JLB).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/dju106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110470PMC
July 2014

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Clin Cancer Res 2014 Jun 31;20(11):3033-43. Epub 2014 Mar 31.

Authors' Affiliations: Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota; Lehigh Valley Hospital, Allentown, Pennsylvania; and Ohio State University, Columbus, Ohio

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040326PMC
June 2014

Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer.

Hepat Oncol 2014 Jun 9;1(3):331-345. Epub 2014 Sep 9.

Division of Medical Oncology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210-1280, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/hep.14.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095158PMC
June 2014

FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?

Oncologist 2013 ;18(5):487-9

Section of Gastrointestinal Oncology, Division of Medical Oncology, Department of Medicine, The Ohio State University/Arthur James Cancer Hospital and Richard Solove Research Institute, Columbus, Ohio 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662837PMC
December 2013

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Clin Cancer Res 2013 Dec 4;19(24):6957-66. Epub 2013 Oct 4.

Authors' Affiliations: Division of Medical Oncology; Alliance Statistics and Data Center, Duke University Medical Center; Durham, North Carolina; Section of Hematology/Oncology, University of Chicago Cancer Research Center; Chicago, Illinois; Department of Surgery, Brigham and Women's Hospital & Harvard Medical School; Boston, Massachusetts; Department of Internal Medicine, Ohio State University; Columbus, Ohio; and Division of Medical Oncology, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-0926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219241PMC
December 2013

Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.

Cancer 2013 Dec 16;119(24):4223-30. Epub 2013 Sep 16.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28358DOI Listing
December 2013

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

J Natl Cancer Inst 2013 Dec 14;105(23):1789-98. Epub 2013 Nov 14.

Affiliations of authors: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (SO, XL, YI, MY, NJM, KN, RJM, JAM, CSF); Department of Pathology (SO), Channing Division of Network Medicine, Department of Medicine (DS, CSF), and Department of Surgery (MMB), Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology (SO, DS) and Department of Biostatistics (DS) , Harvard School of Public Health, Boston, MA; Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC (DN); Memorial Sloan-Kettering Cancer Center, New York, NY (LBS); Hôpital du Sacré-Coeur de Montréal, Montreal, Canada (RW); Loyola University Stritch School of Medicine, Maywood, IL (AH); current: Edward Cancer Center, Naperville, IL (AH); Northwestern University, Chicago, IL (ABB); Toledo Community Hospital Oncology Program, Toledo, OH (RBM); Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH (RMG).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848984PMC
December 2013

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Clin Cancer Res 2013 Oct 27;19(20):5777-87. Epub 2013 Aug 27.

Authors' Affiliations: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; Department of Biostatistics and Bioinformatics, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina; Dana-Farber Cancer Institute; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts; The Ohio State University, Columbus, Ohio; National Cancer Institute, Bethesda, Maryland; and Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122229PMC
October 2013

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

J Clin Oncol 2013 Oct 9;31(29):3664-72. Epub 2013 Sep 9.

Frank A. Sinicrope, Michelle R. Mahoney, Thomas C. Smyrk, Stephen N. Thibodeau, Garth D. Nelson, Daniel J. Sargent, and Steven R. Alberts, Mayo Clinic, Mayo Cancer Center and the North Central Cancer Treatment Group, Rochester, MN; Robert S. Warren, University of California San Francisco, San Francisco, CA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; and Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.48.9591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789216PMC
October 2013

How we treat metastatic colon cancer in older adults.

J Geriatr Oncol 2013 Oct 18;4(4):295-301. Epub 2013 Aug 18.

Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 300 West 10th Avenue, Suite 519C, Columbus, OH 43210-1280, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2013.07.007DOI Listing
October 2013

What is the optimal neo-adjuvant treatment for liver metastasis?

Ther Adv Med Oncol 2013 Jul;5(4):221-34

Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834013485111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707339PMC
July 2013

Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.

Clin Colorectal Cancer 2013 Jun 12;12(2):95-102. Epub 2013 Jan 12.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2012.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790266PMC
June 2013

Colorectal cancer in 2012: Revisiting landmark trials and identifying new therapies.

Nat Rev Clin Oncol 2013 Feb 8;10(2):71-2. Epub 2013 Jan 8.

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210-1280, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.227DOI Listing
February 2013